top of page

AAV vectors that are safe and efficient
Innovative Gene Therapy for Hemophilia
and other Human Liver Diseases

Advancing vector-based gene therapy treatments
Our Platform

Hemophilia B & A
Tackling human liver diseases with groundbreaking efficiency

Hemophilia B & A
1.3M+ global patients
Affecting more than 1.3 million patients globally, hemophilia B & A are bleeding disorders caused by a lack of specific blood clotting factors primarily produced in the liver.
Hemophilia A, the more common form, affects about 1 in 5,000 males and involves a deficiency of factor VIII (hFVIII).
Hemophilia B, affecting about 1 in 30,000, results from a deficiency of factor IX (hFIX).
bottom of page
